RNAi Therapeutics Market is estimated to be worth USD 9.2 billion in 2030, predicts Roots Analysis
The potentialtherapeutic applications of RNAi were realized almost immediately after the phenomenonwas first described; over the years, developers have gradually progressed theirproprietary drug candidates with cautious optimism
Roots Analysis is pleased toannounce the publication of its recent study, titled, “RNAiTherapeutics Market (2ndEdition), 2019-2030.”
The “RNAi Therapeutics Market (2nd Edition),2019-2030: Focus On siRNA, miRNA, shRNA and DNA” report features an extensivestudy of the current market landscape and future opportunities associated withRNAi therapeutics. The study also features a detailed analysis of key driversand trends within this evolving market. Amongst other elements, the reportincludes:
§ Adetailed assessment of the current market landscape of drug developers engagedin the development of RNAi therapeutics.
§ Acompetitiveness analysis of key players engaged in this domain, evaluatingtheir respective product portfolios, type of RNAi molecule, target therapeuticareas, company size and year of establishment
§ Adetailed analysis of more than 70 completed, ongoing and planned clinicalstudies of RNAi therapeutics.
§ Adetailed analysis of various patents that have been filed / granted related toRNAi therapeutics, since 2014
§ Ananalysis of the partnerships that have been established in this domain, in therecent past.
§ Ananalysis of the investments made at various stages of development in companiesengaged in this domain.
§ Ananalysis of the key promotional strategies that have been adopted by developersof marketed oligonucleotide therapeutics, namely Defitelio®, Exondys® andOnpattro®.
§ Detailedprofiles of RNAi Therapeutics that are in the late stage clinical development
§ A detailed market forecast, featuring analysis of the currentand projected future opportunity across key market segments (listed below)
- Key Therapeutic Areas
§ Oncologicaldisorders
§ Infectiousdiseases
§ Geneticdisorders
§ Ophthalmicdisorders
§ Hepaticdisorders
§ Respiratorydisorders
- Type of RNAi molecule
§ siRNA
§ miRNA
§ shRNA
§ sshRNA
§ DNA
- Route of administration
§ Subcutaneous
§ Intravenous
§ Intradermal
§ Intravitreal
§ Oral
§ Intramuscular
- Key geographical regions
§ NorthAmerica
§ Europe
§ AsiaPacific and the Rest of the world
- Leading Player
Keycompanies covered in the report
§ Quark Pharmaceuticals
§ AlnylamPharmaceuticals
§ DicernaPharmaceuticals
§ Souzhou Ribo LifeSciences
§ Olix Pharmaceuticals
§ Sirnaomics
§ Ariz PrecisionMedicine
§ ArrowheadPharmaceuticals
§ Gradalis
§ Benitec Biopharma
Formore information please click on the following -
Other Recent Offerings
1. Gene Therapy Market (3rdEdition), 2019-2030
2. Global T-Cell (CAR-T,TCR and TIL) Therapy Market (4th Edition), 2019-2030
3. Biopharma ContractManufacturing Market (3rd Edition), 2019-2030
About Roots Analysis
Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
